Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 low- and middle-income countries (LMICs), with first supplies due by the end of 2026.
|Videos|March 18, 2020
What "Ending the HIV Epidemic" Entails
Author(s)Contagion® Editorial Staff
Ian Frank, MD, explains the "Ending the Epidemic" initiative.
Advertisement
Segment Description: Ian Frank, MD, Professor of Medicine at the Perelman School of Medicine, University of Pennsylvania, explains the "Ending the Epidemic" initiative.
Interview Transcript (modified slightly for readability):
Frank: Let me remind people of what the "ending the epidemic" initiative is about. 48 cities, or states, are responsible for the majority of new cases of HIV infection. The goal is to prioritize treatment and prevention services in these areas. In order to eliminate new infections, money's going from the Center for Disease Control to health departments in these areas.
Each of the jurisdictions are coming up with their own plan to try to encourage HIV testing, linkage and retention and care, getting people on antiretroviral therapy and for people at risk getting them to adhere to PrEP or adopt other prevention services.
So the initiative has really just begun. And we need more research in order to understand how to most effectively deliver these services to large proportions of individuals.
Advertisement
Related to this article
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
2
Half of Long COVID Patients Substantially Improve Within 3 years
3
Early Metformin Linked to 53% Lower Risk of Long COVID or Death
4
From Pathogen to Infectious Disease Diagnosis: Reflex Testing Targets Hepatitis D Gap
5